Notable Labs appoints Kaile Zagger as Interim CEO and Chief Restructuring Officer

Notable Labs, Ltd.

Kaile Zagger appointed Interim CEO and CRO, effective September 16, 2024.
Dr. Joseph Wagner steps down as interim CEO but remains Chief Scientific Officer.
Zagger is Managing Director at Province, LLC; services provided at $900/hour.
Zagger has over 20 years healthcare experience, including distressed turnarounds.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Kaile A. Zagger

Interim Chief Executive Officer and Chief Restructuring Officer

Notable Labs, Ltd.

Effective: 2024-09-16
Filed: September 16, 2024, 7:59 PM ET

On September 16, 2024, Notable Labs, Ltd. (the “Company” or “Notable”) appointed Kaile A. Zagger as its Interim Chief Executive Officer and Chief Restructuring Officer.

Role change

Joseph Wagner

Chief Scientific Officer

Notable Labs, Ltd.

Effective: 2024-09-16
Successor: Kaile A. Zagger
Filed: September 16, 2024, 7:59 PM ET

Effective September 16, 2024, Dr. Joseph Wagner, the Company’s Chief Scientific Officer, who was also acting as Chief Executive Officer on an interim basis, stepped down from his position as interim Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kaile A. Zagger was appointed as Interim Chief Executive Officer and Chief Restructuring Officer at Notable Labs, Ltd..

Action: appointed
Role: Interim Chief Executive Officer and Chief Restructuring Officer

Exact text from the filing

On September 16, 2024, Notable Labs, Ltd. (the “Company” or “Notable”) appointed Kaile A. Zagger as its Interim Chief Executive Officer and Chief Restructuring Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Wagner changed role as Chief Scientific Officer at Notable Labs, Ltd..

Action: stepped down
Role: Chief Scientific Officer

Exact text from the filing

Effective September 16, 2024, Dr. Joseph Wagner, the Company’s Chief Scientific Officer, who was also acting as Chief Executive Officer on an interim basis, stepped down from his position as interim Chief Executive Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-24-036378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.